CCL

Összesen 3 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM065233
Első szerző:Canestraro, Martina
Cím:Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders / Martina Canestraro, Sara Galimberti, Hakan Savli, Giuseppe Alberto Palumbo, Daniele Tibullo, Balint Nagy, Francesca Guerrini, Simona Piaggi, Naci Cine, Maria Rita Metelli, Mario Petrini
Dátum:2010
ISSN:0165-4608
Megjegyzések:Both arsenic trioxide (ATO) and bortezomib show separate antileukemic activity. With the purpose of evaluating whether the combination of ATO and bortezomib would be an option for patients with acute leukemia, we incubated HL60 leukemic cells with ATO alone and in combination with bortezomib. ATO and bortezomib cooperated to induce cell death and to inhibit proliferation and apoptosis in a synergistic way. The combined treatment resulted in a stronger activation of caspase 8 and 9, moderate activation of caspase 3, and increased expression of Fas and tumor necrosis factor?related apoptosis-inducing ligand (TRAIL)-DR5 receptors. When bortezomib was added, some proapoptotic genes (CARD9, TRAIL) were upregulated, and some antiapoptotic genes (BCL2, BCL3, FLICE) were downregulated. When coincubated, approximately 80% of cells showed altered mitochondrial membrane permeability. Moreover, ATO alone and in combination with bortezomib abrogated DNA-binding activity of nuclear factor kappa beta (NF-?B). Gene expression assays showed that more deregulated genes were related to proliferation of leukocytes, tumorigenesis, control of cell cycle, hypoxia and oxidative stress, cytokines, PI3K-AKT, ERK-MAPK, EGF pathways, and ubiquitination. Finally, in three cases of acute myeloid leukemia, the addition of bortezomib to ATO significantly increased cytotoxicity. We conclude that the combination of bortezomib and ATO may be efficacious in the treatment of myeloid disorders.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
bortezomib
synergestic
antiproliferative
Megjelenés:Cancer Genetics And Cytogenetics 199 : 2 (2010), p. 110-120. -
További szerzők:Galimberti, Sara Savlı, Hakan Palumbo, Giuseppe Alberto Tibullo, Daniele Nagy Bálint (1956-) (molekuláris genetikus) Guerrini, Francesca Piaggi, Simona Cine, Naci Metelli, Maria Rita Petrini, Mario
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM065229
035-os BibID:(PMID)21115902
Első szerző:Galimberti, Sara
Cím:ITF2357 Interferes with Apoptosis and Inflammatory Pathways in the HL-60 Model : a Gene Expression Study / Sara Galimberti, Martina Canestraro, Hakan Savli, Giuseppe Alberto Palumbo, Daniele Tibullo, Balint Nagy, Simona Piaggi, Francesca Guerrini, Naci Cine, Maria Rita Metelli, Mario Petrini
Dátum:2010
ISSN:0250-7005
Megjegyzések:Background: Cytotoxic and pro-apoptotic effectsexerted by the histone deacetylase inhibitor ITF2357 havebeen reported in acute myeloid leukemia HL-60 cells. In thecurrent study, its mechanism of action was investigated at themolecular level. Materials and Methods: Cell proliferationwas evaluated by methyl thiazol tetrazolium bromidereduction; apoptosis by annexin V, mitochondrialtransmembrane potential by tetramethylrhodamine ethylester. Functional experiments and gene expressionevaluations were performed by flow cytometry, microarray,and quantitative polymerase chain reaction. Results:Significant cell growth inhibition and increased apoptosiswere observed. ITF2357 reduced protein levels of BCL-2,MCL-1, and BCL-X, and increased levels of BAK. Exposureto ITF2357 did not abrogate NF-?B DNA binding. Aftermicroarray analysis, interleukin-10, interleukin-6, epidermalgrowth factor, peroxisome proliferator-activated receptor(PPAR), transforming growth factor ?, P38 mitogenactivatedprotein kinase, aryl hydrocarbon receptor,xenobiotic metabolism, PPAR/retinoic acid receptor, NF-?B,apoptosis, lipopolysaccharide/interleukin-1, G-proteinreceptor, T-cell receptor, and platelet-derived growth factorwere the de-regulated pathways. Conclusion: This studyshows that ITF2357 influences both proliferation andinflammatory pathways in HL-60 cells; this observationcould have possible applications in clinical practice.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
gene expression
pathways
apoptosis
Inflammatory
Megjelenés:Anticancer Research. - 30 (2010), p. 4025-4035. -
További szerzők:Canestraro, Martina Savlı, Hakan Palumbo, Giuseppe Alberto Tibullo, Daniele Nagy Bálint (1956-) (molekuláris genetikus) Piaggi, Simona Guerrini, Francesca Cine, Naci Metelli, Maria Rita Petrini, Mario
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM065423
Első szerző:Galimberti, Sara
Cím:Evaluation of the MDR1, ABCG2, Topoisomerases IIα and GST[pi] gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen / Sara Galimberti, Balint Nagy, Edoardo Benedetti, Simone Pacini, Stefania Brizzi, Francesco Caracciolo, Federico Papineschi, Elena Ciabatti, Francesca Guerrini, Rita Fazzi, Martina Canestraro, Mario Petrini
Dátum:2009
ISSN:1042-8194
Megjegyzések:The genomic profile of mantle cell lymphoma (MCL) has been reported to be significantly different from that of otherindolent lymphoproliferative disorders, Topoisomerase IIa, glutathione-s-transferasep (GSTp) and ABCG2 (BCRP)chemoresistance genes being over-expressed in MCL. In our study, expression levels of the above mentioned genes plusMDR1 were tested on bone marrow samples from 20 patients treated with Rituximab plus hyper-CVAD regimen, in order toevaluate a possible impact of the chemoresistance phenomenon on this promising treatment regimen. All patients expressedABCG2 and MDR1 genes; 85% of cases expressed GSTp and topoisomerase IIa. Only ABCG2 were over-expressed incomparison both with marrow from healthy donors and tonsilar CD5?/CD20? lymphocytes (adopted as normal counterpart of the neoplastic population). The overall response rate of the entire series was 87.5%, with 44% of complete responses.Fifty-seven percent of patients achieved the clearance of minimal residual disease. Levels of tested genes did not condition either quality of clinical response or PFS (76% at 24 months). Nevertheless, an ABCG2 higher expression appeared associated with a worse PFS and levels of this gene paralleled the status of minimal residual disease. A further evaluation ofABCG2 expression in larger series of MCL patients would be suitable.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
MDR1
ABCG2
topoisomerases
mantle
cell
lymphoma
Megjelenés:Leukemia & Lymphoma. - 48 : 8 (2009), p. 1502-1509. -
További szerzők:Nagy Bálint (1956-) (molekuláris genetikus) Benedetti, Edoardo Pacini, Simone Brizzi, Stefania Caracciolo, Francesco Papineschi, Federico Ciabatti, Elena Guerrini, Francesca Fazzi, Rita Canestraro, Martina Petrini, Mario
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1